Kelly WK - Search Results

1

Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.

Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N, Scher HI. Morris MJ, et al. Among authors: kelly wk. Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):6-13. doi: 10.1097/00129039-200503000-00002. Appl Immunohistochem Mol Morphol. 2005. PMID: 15722787 Clinical Trial.

2

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin.

Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Schultz PK, et al. Among authors: kelly wk. Urology. 1994 Aug;44(2):237-42. doi: 10.1016/s0090-4295(94)80138-x. Urology. 1994. PMID: 7519382 Free article. Clinical Trial.

3

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Ghossein RA, et al. Among authors: kelly wk. J Clin Oncol. 1995 May;13(5):1195-200. doi: 10.1200/JCO.1995.13.5.1195. J Clin Oncol. 1995. PMID: 7537803

4

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2208-13. doi: 10.1200/JCO.1995.13.9.2208. J Clin Oncol. 1995. PMID: 7545218 Clinical Trial.

5

Hormone-refractory (D3) prostate cancer: refining the concept.

Scher HI, Steineck G, Kelly WK. Scher HI, et al. Among authors: kelly wk. Urology. 1995 Aug;46(2):142-8. doi: 10.1016/s0090-4295(99)80182-4. Urology. 1995. PMID: 7624983 Free article. Review.

6

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2214-22. doi: 10.1200/JCO.1995.13.9.2214. J Clin Oncol. 1995. PMID: 7666079 Clinical Trial.

7

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

Kelly WK, Scher HI. Kelly WK, et al. J Urol. 1993 Mar;149(3):607-9. doi: 10.1016/s0022-5347(17)36163-3. J Urol. 1993. PMID: 7679759

8

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Kelly WK, et al. J Clin Oncol. 1993 Apr;11(4):607-15. doi: 10.1200/JCO.1993.11.4.607. J Clin Oncol. 1993. PMID: 7683043

9

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Scher HI, Kelly WK. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 1993 Aug;11(8):1566-72. doi: 10.1200/JCO.1993.11.8.1566. J Clin Oncol. 1993. PMID: 7687666

10

Prostate cancer: how can a common disease be so controversial?

Kelly WK, Scher HI. Kelly WK, et al. Curr Opin Oncol. 1994 May;6(3):318-31. Curr Opin Oncol. 1994. PMID: 8080862 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

234 results

Search Page

Filters